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A
D is the amount of denosumab in the subcutaneous depot compartment, A tot the total amount of denosumab in the central compartment, A P the amount of denosumab in the peripheral compartment, R tot the total RANKL level (including both free RANKL and RANKL bound to denosumab). CL tot is denosumab total clearance, C the serum free denosumab concentration. k a is the absorption rate constant, CL lin the denosumab linear clearance, k int the elimination rate constant of drug-target (here denosumab-RANKL) complex, V 1 the volume of distribution in the central compartment, K SS the steady-state constant, Q the intercompartment clearance, V 2 the volume of distribution in the peripheral compartment, k syn the synthesis rate of RANKL, k deg the degradation rate constant of RANKL.
Composite criterion to select the best reduced model [15]
A final lumped model was selected using the following composite criterion: Table 2 Table 3 of [11] ) in the bone biology model were provided to calculate the missing SE values due to differences between the original and later-published papers [11, 12] . Log-normal distributions were assumed for each parameter. A total of 250 datasets were simulated to create a credible interval of original predictions. 
